Compare Humana Inc (HUM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Humana Inc trades at $427.5 (market cap $50.48B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Humana Inc is far larger — about 51.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Humana Inc pays a 0.84% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HUM | MRVI | |
|---|---|---|
Market Cap | $50.48B | $972.90M |
Volume | 1,889,709 | 4,325,710 |
Sector | Health | Health |
52-Week High | $433.50 | $9.00 |
52-Week Low | $163.67 | $2.83 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $57.83B | $1.08B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.
The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
